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S u m m a r y
Introduction. High doses of methotrexate (HD-Mtx) in some patients may cause severe 
adverse effects despite monitoring of Mtx elimination and administering of calcium folinate.
One of the most important enzymes of the folate metabolic pathway affected by Mtx is meth-
ylenetetrahydrofolate reductase (MTHFR) which activity depends on genetic polymorphisms.
Aim. Analysis of occurrence and intensity of Mtx therapy related early toxicities in chil-
dren treated because of acute lymphoblastic leukemia (ALL) in dependency on 677C>T 
MTHFR gene polymorphism.
Material and methods. One hundred and sixty children (age: 1-17 years) treated in 
one pediatric oncology department between 1993 and 2007 according to ALL-BFM-90 and 
ALL-IC-2002 protocols were included into retrospective study. The presence of 677C>T 
MTHFR polymorphism was evaluated with the use of PCR-RFLP technique, and Mtx phar-
macokinetics parameters were evaluated with immunoenzymatic method. Early toxicities 
of 617 chemotherapy cycles (Mtx dose 2 g/m2 and 3 g/m2) were analyzed according to 
NCI-CTC scale.
Results. In analyzed group the patients with wild-type genotype CC, heterozygotes CT 
and homozygotes TT were 42.5, 48.75 and 8.75%, accordingly. Nausea and vomiting 
were significantly more common in CT heterozygotes (p = 0.03). In TT patients delays 
of therapy (p = 0.01), thrombocytopenia (p = 0.03) and acute neurotoxicities (p = 0.05) 
were more common.
More severe liver toxicities, nausea, stomatitis, and infections were observed in TT 
homozygotes. Acute renal insufficiency of unknown etiology occurred in two patients 
(CT heterozygote and TT homozygote).
Conclusions. Obtained results indicate the possible correlation between the presence 
of T allel and high risk of acute toxicities of HD-Mtx therapy in children. It is necessary to 
continue studies including higher number of patients with evaluation of other important 
genetic polymorphisms.
S t r e s z c z e n i e
Wstęp. Wysokie dawki metotreksatu (HD-Mtx) pomimo monitorowania eliminacji leku 
i podaży leukoworyny u niektórych pacjentów wywołują nasilone objawy toksyczne. Jed-
nym z kluczowych enzymów szlaku przemian folianów, występującym w zmiennej, zależ-
nej od polimorfizmów genowych aktywności, którego działanie zaburza Mtx, jest redukta-
za metylenotetrahydrofolianowa (MTHFR).
Cel pracy. Analiza występowania i nasilenia wczesnych toksyczności terapii HD-Mtx 
u dzieci leczonych z powodu ALL, w zależności od polimorfizmu genowego 677C>T 
MTHFR.
Materiał i metody. Badaniem retrospektywnym objęto 160 dzieci w wieku 1-17 lat, leczo-
nych w jednym ośrodku onkologii dziecięcej w latach 1993-2007 zgodnie ze zmodyfikowanym 
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is a most fre-
quent neoplasm of childhood. With use of multimod-
al, multidrug therapy it can be cured in about 80% of 
cases. Standard chemotherapy is expected to result in 
toxicities that rarely are considered as life-threatening 
ones but in most of the patients these toxicities can 
be strongly pronounced and thus constitute a reason 
for therapy delay what increases a risk of leukemia re-
lapse. Acute toxicities are particularly frequent in case 
of high doses of cytotoxic drugs used in repeated cy-
cles as for example in case of high dose methotrex-
ate (HD-Mtx) administration in remission consolida-
tion phase in ALL (1-4). This cytostatic agent belongs 
to the antimetabolite group of cytostatics. It’s action 
comprises blockage of several enzymes involved in 
folate metabolism pathway what results in block in pu-
rine synthesis, protein methylation inhibition and i.a. 
transformation of homocysteine to methionine (3, 5-9). 
Inhibition of cell divisions resulting from disturbed 
DNA synthesis and repair acts against the leukemic 
cell clone but also injuries healthy tissues, especial-
ly these that undergo rapid cell division as epithelial 
cells, mucosae, and bone marrow. Most frequently ob-
served methotrexate toxicities are: myelosuppression, 
mucositis, skin changes, liver and kidney dysfunction, 
acute neurological toxicities and also infections. Life-
threatening toxicities of high-dose methotrexate ad-
ministration are however relatively rare, of which most 
important one is kidney failure. Prevalence and degree 
of observed toxic side effects of methotrexate results 
mainly from prolonged methotrexate exposition as well 
as individual patient’s susceptibility to that drug. Gene 
polymorphisms resulting in modulation of enzyme ac-
tivity that results in important metabolic pathways mod-
ification has been widely studied lately. Certain gene 
polymorphisms can influence not only the effective-
ness of anti-cancer therapy and risk of relapse but also 
the occurrence and intensity of chemotherapy side ef-
fects (2-6, 8-14). In case of folate metabolic pathways 
that are influenced by methotrexate, methylenetetra-
hydrofolate reductase (MTHFR) activity is of special 
meaning (MTHFR). This enzyme is involved in the equi-
librium of protein methylation processes (including 
homocysteine homeostasis) and urine and thymidine 
synthesis (DNA regeneration) as well. Among abun-
dantly described MTHFR gene polymorphisms, the 
commonly observed 677C>T polymorphism is of 
special relevance as it results in significant decrease 
of MTHFR enzyme activity (10, 11). The prevalence of 
polymorphic T allel varies between different geograph-
ical regions that i.a. are known to differ in nutritional 
habits. This specific allel is most frequently observed 
in mediterranean and central-African population where 
diet is generally considered as folate-rich one. In Cau-
casian population MTHFR activity is observed in about 
half of population as the T allel is present in 40% of 
this population in its heterozygotic CT form and in 
about 10% of population in homozygotic TT form (5, 7, 
10, 11, 15, 16). As a result of heterozygotic CT form oc-
currence and even more in case of 677 nucleotide TT 
homozygosity a thermolabile enzyme of decreased ac-
tivity is produced (60 and 30% of activity, respectively). 
This can influence the individual patient’s methotrexate 
sensitivity. Numerous published papers indicate a re-
lationship between the presence of 677C>T MTHFR 
gene polymorphism and the observed intensity of 
acute methotrexate toxicities both in case of low as 
well as high methotrexate doses use (1, 9, 10, 17-20). 
Some papers indicate a relationship between this gene 
polymorphism and worse treatment results in children 
treated for ALL. These treatment failures may result 
not only from deaths of therapy toxicities (influenced 
i.a. by endothelium dysfunction secondary to hiperho-
mocysteinemia) but also an increased risk of relapse in 
T allel carriers in whom DNS synthesis suppression is 
decreased (1, 2, 21).
AIM
Aim of present paper is analysis of high-dose metho-
trexate acute toxicities frequency and intensity in chil-
dren treated for ALL depending on 677C>T MTHFR 
gene polymorphism presence.
MATERIAL AND METHODS
Retrospective analysis of 160 children with 
ALL (age: 1-17 years), treated from 1993 to 2007 
at Pediatric Oncology and Hematology Department, 
protokołem ALL-BFM-90 i ALL-IC-2002. Nosicielstwo polimorfizmu 677C>T MTHFR oce-
niono techniką PCR-RFLP, a parametry farmakokinetyki Mtx metodą immunoenzymatycz-
ną. Bliskie toksyczności łącznie 617 cykli chemioterapii z zastosowaniem dawki 2 g/m2 
i 3 g/m2 Mtx analizowano zgodnie ze skalą NCI-CTC.
Wyniki. W badanej grupie pacjenci o „dzikim” genotypie CC, heterozygoty CT i homo-
zygoty TT stanowili odpowiednio: 42,5; 48,75 i 8,75%. Nudności i wymioty częściej wystę-
powały u heterozygot CT (p = 0,03). U pacjentów TT odnotowano częstsze: opóźnienia 
w kontynuacji leczenia (p = 0,01), małopłytkowość (p = 0,03) i ostre objawy neurotoksycz-
ne (p = 0,05). Wyższe stopnie toksyczności wątrobowych, nudności, zapalenia śluzówek 
jamy ustnej i zakażeń obserwowano u homozygot TT. Ostra niewydolność nerek o niezna-
nej etiopatogenezie wystąpiła u dwóch pacjentów: heterozygoty CT i homozygoty TT.
Wnioski. Uzyskane wyniki wskazują na związek allela T z większym nasileniem ostrych 
toksyczności terapii HD-Mtx u dzieci. Celowa jest kontynuacja badań z udziałem dużych 
grup pacjentów i uwzględnieniem także innych istotnych polimorfizmów genowych.
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Polish-American Institute of Pediatrics, Jagiello-
nian University Medical College in Kraków with 
high-dose methotrexate as a consolidation ALL 
therapy (doses: 2 g/m2 – modified ALL-BFM-90 
protocol and 3 g/m2 – ALL-IC-BFM-2002 proto-
col) was performed. Therapy inclusion criteria 
comprised: good general status of the patient, no 
evidence for acute infections, normal liver and kid-
ney function and elimination of drugs known to in-
terfere with methotrexate metabolism. Therapy was 
administered four times, every two weeks. Patients 
were initially hydrated and received proper alkaliza-
tion prior to 24-hour continuous methotrexate infu-
sion administered with use of volumetric pump and 
central venous access. A lumbar puncture with in-
trathecal methotrexate or methotrexate/cytarabine/
hydrocortisone administration (in case of 3 g/m2 
and 2 g/m2 methotrexate dose respectively) was 
performed within two hours from the beginning of 
methotrexate infusion. Patients also received oral 
mercaptopurine (25 mg/m2) daily. A specific an-
tidote – leucovorin (15 mg/m2) was administered 
in 42, 48 and 54 hour from the start of methotrex-
ate infusion. Methotrexate serum concentration was 
routinely assessed in 24, 36, 42 and 48 hour form 
start of methotrexate infusion (EMIT® – Syva im-
munoenzymatic method, with use of VIVA-Vitalab 
analyzer, DADE-BEHRING, USA). Methotrexate 
serum concentrations obtained after completion 
of methotrexate infusion were considered as rep-
resentative for steady state. Hour 48 serum meth-
otrexate concentration exceeding critical values 
(0.40 µmol/l) resulted in leucovorin dose escalation, 
hydration intensification and in prolonged metho-
trexate serum concentration until safe values were 
reached (< 0.25 µmol/l) in each case. Methotrex-
ate elimination pharmacokinetics were assessed 
with use of first degre elimination constants for both 
phases of methotrexate elimination estimated with 
Wagner’s formula (Kel = lnc1 – lnc2/t2 – t1).
Presence of 677C>T MTHFR gene polymorphism 
was identified in DNA isolated from peripheral blood 
leukocytes with use of PCR-RFLP technique. Starter se-
quences used in DNA amplification reaction were: CTG 
ACC TGA AGC ACT TGA AGG (forward) and AGT GAT 
GCC CAT GTC GGT (reverse). PCR reaction products 
were processed with restriction enzyme Hinfl1, which 
detects the locus of cytosine to thymidine substitution in 
677th nucleotide. Obtained DNA fragments were sepa-
rated with use of agarose gel electrophoresis (fig. 1).
National Cancer Institute Common-Toxicity-Criteria 
in GPOH modification (German Society of Pediatric 
Oncology/Hematology) (22) was used to assess organ 
and systemic toxicities observed during the high-dose 
methotrexate treatment.
An analysis of total of 617 chemotherapy cycles with 
use of 2 g/m2 and 3 g/m2 methotrexate doses was per-
formed. Statistical analyses were performed with use of 
STATISTICA software. Chi-square test and Fisher exact 
test were used to identify relations between qualitative 
features. Consistency of allele separation within ob-
served group of patients with expected allele distribu-
tion according to Hardy-Weinberg’s rule was checked 
with use of the Chi-square test. One-sided fraction test 
was applied to check the influence of 677C>T MTHFR 
gene polymorphism on the incidence of acute HD-Mtx 
therapy toxicities. Multiple logistic regression analy-
sis was performed to identify risk factors of increased 
HD-Mtx therapy toxicities. Statistical results were veri-
fied at the significance level of p = 0.05.
RESULTS
Among 160 analyzed cases treated with HD-Mtx, 
78 (48.75%) were CT heterozygotes, 68 (42.5%) were 
identifies as a wild-type CC gene carriers and 14 (8.75%) 
were TT homozygotes. The distribution of 677C>T 
MTHFR gene polymorphisms within analyze group 
was consistent with the Hardy-Weinberg equation con-
ditions (χ2 = 0.323; p = 0.57).
Two of the most frequent treatment toxicities: liver 
dysfunction (elevated transaminase activity, increased 
serum bilirubin, decreased total protein and albumin 
concentrations) and mucositis were observed in equal 
proportions, independently from the MTHFR genotype 
of the subject. However in CT heterozygotes: nausea 
and vomiting (p = 0.03) and in TT homozygotes: acute 
CNS toxicities, thrombocytopenia and therapy delay 
(p = 0.05, 0.03 and 0.01 respectively) were more fre-
quently observed than in carriers of the wild-type CC 
genotype. Summary of analyses of high-dose metho-
trexate acute toxicities and therapy side effects depend-
ing on 677C>T MTHFR gene polymorphism for 617 cy-
cles analyzed is presented in table 1 and figure 2.
Fig. 1. Result of agarose gel electrophoresis of DNA samples treated 
with Hinfl1 enzyme – 677C>T MTHFR gene polymorphism. From 
left to right: ladder, two samples – CC homozygotes (122bp DNA 
fragments), two samples – CT heterozygotes (two DNA fragments: 
122bp – 677C allel and two sequences of 82bp – 677T allel), two 
samples – TT homozygotes (DNA fragments of 82bp corresponding 
to 677T allel with Hinfl1restriction site).
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Table 1. Acute toxicity frequency in course of HD-Mtx (2 g/m2 and 
3 g/m2) therapy depending on the carrier of T allel of 677C>T 
MTHFR gene polymorphism: analysis of 617 chemotherapy 
cycles.
Treatment 
toxicity
Percentage of chemotherapy cycles depending 
on the genotype, p-value
CT
(n = 304 cycles)
CC
(n = 257 cycles)
TT
(n = 56 cycles)
Hepatic 
toxicity
29.3% 33.5% 30.4%
p = 0.143 p = 0.328
Nausea
23.4% 16.7% 19.6%
p = 0.025 p = 0.301
Infections
14.5% 18.3% 17.9%
p = 0.112 p = 0.472
Stomatitis
11.2% 7.8% 7.1%
p = 0.087 p = 0.429
Diarrhoea
5.6% 5.4% 1.8%
p = 0.459 p = 0.126
Neurotoxicity
2.3% 0.8% 3.6%
p = 0.124 p = 0.05
Skin toxicities
3.0% 2.7% 0.0%
p = 0.416 p = 0.107
Anemia
(1-4 grade)
3.9% 5.4% 7.1%
p = 0.199 p = 0.306
Leukopenia
(1-4 grade)
7.6% 6.2% 7.1%
p = 0.258 p = 0.401
Thrombocy-
topenia
(1-4 grade)
5.6% 3.1% 8.9%
p = 0.077 p = 0.025
Kidney
toxicities
0.7% 0.4% 1.8%
p = 0.343 p = 0.128
Therapy
delay 
> 7 days
4.9% 2.7% 8.9%
p = 0.090 p = 0.014
Intensity of acute toxicities of HD-Mtx therapy for 
three patient 677C>T MTHFR polymorphism groups 
was also analyzed. Liver dysfunction was observed 
in about 30% of chemotherapy cycles irrespective of 
MTHFR genotype. In 92.5% of cycles only transient 
grade 1 toxicity was observed. It usually presented as 
a decrease of total protein and albumin serum concen-
tration. Major hepatotoxicity (grade 3 and 4) were rare 
and occurred in TT homozygotes (1.8% chemothera-
py cycles) more frequently than in CC homozygotes 
(0.4% of cycles). However differences were not sta-
tistically significant (p = 0.49). Mucositis and nausea 
(grade 2 and 3) were observed in allel T carriers (fig. 3) 
but no statistical differences were observed in compari-
son to CC homozygote group (p = 0.14 and 0.20 re-
spectively). Neurotoxicity presenting as seizures and 
irritation with hyperesthesia (grade 2 and 3) were ob-
served in 2 of 160 analyzed patients. These two pa-
tients were identified as CT heterozygotes. Other, less 
pronounced CNS toxicities (grade 1) were consistent 
with typical symptoms of arachnoid irritation and were 
significantly more common (p = 0.05) in children with 
677TT genotype in comparison to patients with 677CC 
genotype. In case of infectious complications, pres-
ence of C allel was correlated to more frequent inci-
dence of upper respiratory tract infection of a mild 
course (grade 1), T allel however was connected to 
more severe complications as pneumonia (grade 2) or 
generalized infections (grade 3) but no statistically sig-
nificant differences were identified (p = 0.36). None of 
patients died of major toxicities resulting from HD-Mtx 
therapy. The most severe complication observed was 
acute kidney failure. It occurred in two girls (3.5 and 
16 years old) during the first HD-Mtx chemotherapy 
cycle administered. In both cases coincidence of well-
known risk factors (i.a. primary kidney dysfunction, 
administration of drugs interfering with methotrexate 
clearance, presence of transsudates, infections) was 
excluded. These two children were carriers of the CT 
and TT 677C>T MTHFR polymorphism.
To identify the factors influencing the intensity of 
acute therapy toxicities, a logistic regression model 
was created which included: methotrexate dose, age, 
BMI, presence of 677C>T MTHFR polymorphisms, 
hour 48 methotrexate serum concentration, late-phase 
Fig. 3. Stomatitis intensity according to NCI-CTC scale depending 
on 677C>T MTHFR gene polymorphism: analysis of 617 chemothe-
rapy cycles.
Fig. 2. Acute toxicity frequency in course of HD-Mtx (2 g/m2 and 3 g/m2) 
therapy depending on the 677C>T MTHFR gene polymorphism: 
analysis of 617 chemotherapy cycles.
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methotrexate elimination constant (Kel 36.-48.). Logis-
tic regression model revealed that hour 48. Serum 
methotrexate concentration is the only statistically 
significant parameter (p = 0.03) for the risk of occur-
rence of at least two different acute toxicities of HD-Mtx 
therapy (fig. 4). No influence of any of variants of 
677C>T MTHFR gene polymorphism on disturbance 
of Mtx elimination was identified.
DISCUSSION
Methotrexate is one of fundamental antimetabo-
lites which have been used in oncological therapy of 
hematopoietic system neoplasms and solid tumors 
since 1948. In ALL treatment it is used as a part of 
consolidation therapy – depending on the treatment 
protocol – in different high-doses as intravenous infu-
sions of variable duration. It is also administered orally 
as a part of maintenance leukemia treatment. Poly-
morphism of genes encoding enzymes of the folate 
metabolism pathway which are essential i.a. for the 
DNA regeneration may be responsible for modification 
of the response to this drug or may influence the oc-
currence of acute treatment toxicities (2, 5, 8-11, 13, 
15, 17, 19, 23, 24). One of well-known polymorphisms 
is the abundantly carried MTHFR C>T 677 polymor-
phism, which results in thermolability of the enzyme 
and it’s substantially decreased activity (1, 10, 11, 15, 
19, 20, 24). The key role of this enzyme in the folate 
metabolic pathway is the maintenance of equilibrium 
between nucleotide production and methylation reac-
tions in the organism. Results published in numerous 
papers indicate that CT genotype and – especially TT 
genotype results in decreased MTHFR activity and it 
also results in increased serum and cerebrospinal 
fluid homocysteine concentration (7, 21). Hiperhomo-
cysteinemia interferes with the endothelium structure 
and may induce serious toxic side effects in numer-
ous organs and systems of the body. It was proved 
that hiperhomocysteinemia is related to grade 4 CNS 
toxicities i.e. thrombotic CNS events and seizures or 
coma occurrence (7). Available evidence for influence 
of 677C>T MTHFR gene polymorphism on metho-
trexate therapy tolerance is unequivocal. Some major 
experts in oncology (i.a. Pui) share the opinion that 
677 TT homozygosity is connected to increased risk of 
mucosal inflammatory reactions of the gastrointestinal 
tract as well as to increased hepatotoxicity. It has been 
observed in low-dose methotrexate schedules howev-
er (9). Some pilot in vitro studies on ALL lymphoblast 
drug sensitivity in children had shown increased drug 
sensitivity in 677 TT homozygotes (18). Ulrich, as one 
of the first authors described the relationship between 
the presence of TT allele and increased mucosal tox-
icities and longer hematopoietic reconstitution (mainly 
due to prolonged thrombocytopenia) in a group of 
220 patients treated for AML with use of methotrex-
ate as a part of conditioning treatment before the al-
logeneic hematopoietic stem cell transplantation (19). 
In adult patients treated with methotrexate as a part of 
conditioning treatment before the allogeneic hemato-
poietic stem cell transplantation as a graft-versus-host 
reaction prophylaxis statistically significant correlation 
between the presence of 677 TT genotype and hepa-
totoxicity (p = 0.04) and slower platelet reconstitu-
tion (p = 0.01) was observed (25). It was shown that 
presence of T allel results in statistically significant in-
crease in frequency of thrombocytopenia (p = 0.02) 
in a group of 181 children treated for ALL with HD-
Mtx (17). El-Khodary has analyzed ALL therapy with 
use of 2 g/m2 of methotrexate in 40 children and found 
that there had been statistically significant increase 
in myelotoxicity (grade 3 and 4) and hepatotoxicity 
(2 grade) in 677C>T MTHFR gene variant carriers (1). 
In a multicenter polish study, analyzing 7 different 
gene polymorphisms, 389 children were observed 
and a significant correlation between T allel 677C>T 
MTHFR presence and increased risk of death due to 
therapy toxicities (p = 0.03) was observed, moreover 
1/3 of the relapses occurred in TT homozygotes. Most 
of deaths occurred in intermediate and high-risk group 
of patients, in T-ALL and in children with poor response 
to initial therapy, who were intensively treated. Among 
20 of 30 (64.5%) deaths that occurred were deaths in 
remission and in most of the cases they resulted from 
infections and bleeding episodes in period of bone 
marrow aplasia. The authors had formulated a hypoth-
esis that hiperhomocysteinemia resulting from de-
creased MTHFR activity may prone to heavily course 
of infections, vascular endothelium dysfunction and 
deaths resulting from multiorgan failure. They do also 
propose that chemotherapy intensity reduction should 
be considered in 677 TT homozygotes (21). In a study 
conducted by Aplenc et al. 520 children treated with 
low Mtx doses as a part of ALL maintenance treatment 
were observed. No influence of MTHFR 677C>T poly-
morphism on incidence of acute therapy toxicities (in-
cluding infections) was identified (5). Presence of T al-
lel was connected to statistically significant (p = 0.04) 
Fig. 4. Odds ratio and confidence interval for parameters influen-
cing the occurrence of at least two different Mtx (2 g/m2 and 3 g/m2) 
chemotherapy toxicities.
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increase of risk of relapse in a multiparameter Cox 
model (including age, initial WBC, initial response to 
therapy). Basing on this observation a hypothesis on 
influence of analyzed polymorphism on decrease of 
cytotoxic Mtx activity was proposed. Decrease MTHFR 
activity results in accumulation of 5,10-metylenetetra-
hydrofolates which are substrates for thymidilate syn-
thase but it can also activate the parallel DNA produc-
tion path and lead to increased DNA renewal. Similar 
observations were made by El-Khodary who analyzed 
40 children treated due to ALL. Significantly lower EFS 
rates were observed in T allel carriers of 677C>T MTHFR 
gene polymorphism (1).
It should be mentioned that numerous papers 
showing relationship of T allel 677 C>T MTHFR gene 
polymorphism to increased acute Mtx therapy tox-
icities refer to prolonged use of low Mtx doses in pa-
tients treated due to ALL and rheumatoid diseases as 
well (16, 20). Toleration of low Mtx doses used typically 
in ALL maintenance treatment was assessed by Japa-
nese investigators who found that there is a relation-
ship between the presence of T allel and chemotherapy 
gaps due to its hematologic or hepatic toxicities (26). 
Also in one study conducted in adults significantly 
higher incidence of hepatic, intestinal and hematologi-
cal toxicities of maintenance therapy was identified in 
677 TT genotype carriers. Compromised liver function 
and leucopenia were almost five times more frequent 
in TT genotype carriers in comparison with CC geno-
type homozygotes (2). Another publication focusing 
on patients treated with low methotrexate doses due to 
ovarian cancer there was significantly higher incidence 
of hematological toxicities (grade 3 and 4) and muco-
sitis described (p = 0.0001) in case of TT genotype in 
comparison with CT and CC variants (24).
However other papers have shown alternative opin-
ions. Costea et al. in a study comprising 186 pediat-
ric patients shown that in carriers of the T allel there 
was much less frequent incidence of major (grade 3 
and 4) hematological and hepatic toxicities in course 
of low methotrexate dose treatment in consolidation 
and maintenance ALL therapy. Earlier study by Costea 
had indicated (as study of Aplenc) a relationship be-
tween the presence of T allel and lower EFS rates what 
made the author propose a controversial opinion on 
methotrexate dose escalation in TT homozygotes dur-
ing maintenance therapy (10). De Jonge et al. in an 
in vitro study performed in 157 patients did not show 
an influence of the presence of T allel on methotrex-
ate sensitivity of leukemic cells (6). Other papers have 
also not shown any relation between 677C>T MTHFR 
polymorphism with increased HD-Mtx therapy toxici-
ties (7, 13, 23, 27-29). The lack of unequivocal opinions 
on the influence of 677C>T MTHFR gene polymor-
phism on acute Mtx therapy toxicities may be related 
to small number of study subjects in analyzed patient 
groups, differences between used therapy protocols, 
possible interactions with other drugs, diet, influence 
of ethnic and environmental factors on individual folate 
metabolism and other important gene polymorphisms 
with possible correlation that were not analyzed (1, 7, 
23, 27, 29).
In the present study a series of 617 analyzed chemo-
therapy cycles more frequent or increased toxicities were 
observed for: nausea and vomiting, thrombocytopenia, 
therapy delay due to observed toxicities, or acute neuro-
logical toxicities in a T allel 677C>T MTHFR gene poly-
morphism carriers than in CC patients. Reports about 
the most serious HD-Mtx toxicity i.e. acute kidney fail-
ure are still incidental but information on the possible 
relation of this toxicity to the TT variant of 677C>T 
MTHFR polymorphism is available (30). Patient’s sensi-
tivity to HD-Mtx therapy is related not only to numerous 
well-known factors as patient’s age, hydration, drug 
interactions etc. but is also related to genetic factors 
which are being intensively studied by numerous in-
vestigators. It can be assumed that polymorphisms of 
other genes involved in different compounds of folate 
pathway, not studied in present paper may influence 
the tolerance of HD-Mtx therapy or they may mutually 
correlate (4, 12, 13).
CONCLUSIONS
Polymorphisms of genes involved in: transport of 
methotrexate to the cells, synthesis of more efficient 
polyglutamates and folate pathway can modify the 
antimetabolic effect of HD-Mtx therapy and result 
in increased therapy toxicity. To investigate the rel-
evance of these genes more studies on large and 
homogeneous patient groups should be performed 
with special focus on polymorphisms of other genes 
involved in Mtx mechanisms of action i.a. transport 
proteins, family of multi-drug resistance proteins, 
and other enzymes of folate pathway. Pharmacoge-
nomic studies are hoped to have additional impact 
on further progress in ALL treatment.
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